deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03206918

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Sponsor: BeiGene

Conditions Relapsed or Refractory Chronic Lymphocytic Leukemia Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions Zanubrutinib
Updated 15 times since 2017 Last updated: Oct 23, 2024 Started: Mar 9, 2017 Primary completion: Jun 15, 2018 Completion: Sep 10, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03206918, this PHASE2 trial focuses on Relapsed or Refractory Chronic Lymphocytic Leukemia and Relapsed or Refractory Small Lymphocytic Lymphoma and remains completed. Sponsored by BeiGene, it has been updated 15 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Oct 2021 — Nov 2021 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Apr 2021 — Oct 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Aug 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations